Keros Therapeutics, Inc.
KROS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.29 | 0.04 | -0.00 | 0.15 |
| FCF Yield | 0.49% | -5.60% | 38.86% | -7.25% |
| EV / EBITDA | 2.17 | 4.00 | -1.90 | -3.35 |
| Quality | ||||
| ROIC | -1.78% | -5.12% | 19.06% | -9.08% |
| Gross Margin | 97.23% | 97.96% | 100.00% | 89.09% |
| Cash Conversion Ratio | -0.45 | 0.97 | 1.09 | 1.00 |
| Growth | ||||
| Revenue 3-Year CAGR | 3,035.96% | 6,151,975.89% | 5,987,959.59% | 1,525,390.30% |
| Free Cash Flow Growth | 110.27% | -118.89% | 446.90% | -49.90% |
| Safety | ||||
| Net Debt / EBITDA | 43.94 | 20.65 | -4.61 | 18.57 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -501.56 | -1,202.81 | -1,727.91 | -1,115.70 |